Coartem (Novartis) — originator brand; WHO prequalified; most widely used globally · Coartem Dispersible (Novartis) — paediatric dispersible formulation (not the adult formulation but same compound) · Riamet (Novartis) — brand name used in Europe and some high-income markets · Artemether/Lumefantrine Tablets 20/120 mg (multiple WHO-prequalified generic manufacturers: Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceutical — generic brands widely used in sub-Saharan Africa including Uganda)
Clinical safety rating: caution
Animal studies have demonstrated safety
Artemether (and its active metabolite DHA): Artemether is a lipid-soluble methyl ether derivative of artemisinin. Following absorption, it is rapidly converted to DHA by hepatic CYP3A4/CYP2B6. DHA is the primary active moiety. The endoperoxide bridge (1,2,4-trioxane ring) is the pharmacophore — in the presence of intraparasitic iron (haem iron from haemoglobin digestion), the endoperoxide bridge undergoes reductive cleavage generating highly reactive carbon-centred free radicals and reactive oxygen species. These alkylate haem (forming haem-drug adducts), parasite proteins, and critical enzymes including PfATP6 (a SERCA calcium ATPase orthologue) and other membrane proteins, causing irreversible oxidative damage to the parasite. Artemether/DHA acts rapidly on all intraerythrocytic parasite stages (rings, trophozoites, schizonts) and reduces parasite biomass by approximately 10,000-fold per 48-hour parasite cycle. It also has gametocytocidal activity against stage I–III gametocytes, reducing transmission potential. Lumefantrine: A synthetic racemic fluorene derivative structurally related to halofantrine and quinine. Mechanism not fully elucidated. Lumefantrine accumulates in the parasite food vacuole and is postulated to inhibit the biocrystallisation of toxic haem into inert haemozoin (malaria pigment), leading to haem accumulation and oxidative parasite death — similar to chloroquine's mechanism but with distinct structural binding. Lumefantrine acts predominantly on late trophozoite and schizont stages, complementing artemether's pan-stage activity. Its long half-life provides a prolonged post-treatment prophylactic effect, clearing residual parasites and preventing early recrudescence. Synergy: The artemether component provides rapid, massive parasite clearance (>99.9% within 48 hours), while lumefantrine eliminates residual parasites and provides 4–6 weeks of post-treatment suppression in endemic settings.
| Metabolism | Artemether: Rapidly and extensively metabolised by hepatic CYP3A4 (primary) and CYP2B6 (secondary) to dihydroartemisinin (DHA) — the pharmacologically active metabolite responsible for the majority of antimalarial effect. DHA is subsequently glucuronidated (UGT1A9, UGT2B7) to inactive DHA-glucuronide and excreted renally and in bile. Artemether is an auto-inducer of CYP3A4 with repeated dosing over the 3-day course, leading to modestly reduced artemether and DHA AUC with subsequent doses (auto-induction effect). In pregnancy, CYP3A4 activity is upregulated (~30–50% increase), further increasing artemether-to-DHA conversion and potentially reducing artemether AUC — clinical significance at standard doses is uncertain. Lumefantrine: Primarily metabolised by hepatic CYP3A4 to desbutyl-lumefantrine, an active metabolite. CYP3A4 induction (by artemether, rifampicin, antiretrovirals) reduces lumefantrine exposure. CYP3A4 inhibition (by some protease inhibitors) increases lumefantrine exposure and QTc risk. Lumefantrine undergoes minimal renal excretion. It is predominantly eliminated via faeces/bile. Pregnancy-specific pharmacokinetic changes: Multiple PK studies in pregnant African women have demonstrated that pregnancy significantly reduces lumefantrine AUC (by ~30–40% in T2/T3 compared to non-pregnant adults and post-partum women), primarily due to increased volume of distribution (expanded plasma volume) and increased CYP3A4 activity. Artemether/DHA AUC is also reduced. These PK changes translate to lower drug exposure per standard dose in pregnancy, raising concerns about potential reduced efficacy in high-transmission settings — however, current WHO guidelines do not yet recommend dose adjustment pending completion of definitive pharmacokinetic-pharmacodynamic trials (STOPPAM, PREGACT follow-up studies). |
Dosing varies by indication and patient profile. Always follow your institution's current prescribing guidelines.
| Renal impairment | Consult protocols for adjustment. |
| Liver impairment | Consult protocols for adjustment. |
| 1st trimester | Caution — use when benefit outweighs risk, which is almost always the case with active falciparum malaria. WHO 2023 guidelines state that ACTs including AL are acceptable in the first trimester when they are the only effective treatment available, acknowledging that untreated falciparum malaria poses far greater risk (miscarriage, maternal death) than the theoretical teratogenic risk extrapolated from animal data. Preferred regimen where feasible remains quinine 10 mg/kg PO TID × 7 days plus clindamycin 450 mg PO TID × 7 days. If quinine is unavailable, not tolerated, or where compliance with the 7-day quinine regimen is unlikely, AL is appropriate. Animal embryotoxicity data at supratherapeutic doses should not preclude treatment in an acutely ill pregnant woman. Document indication, gestational age, and treatment rationale clearly. |
| 2nd trimester | First-line. WHO-recommended treatment for uncomplicated P. falciparum malaria. Administer as standard 6-dose regimen with fatty food. Monitor for hypoglycaemia, anaemia, and preterm labour as malaria complications. Lumefantrine AUC is reduced in pregnancy — reassess at Day 28 for recrudescence or re-infection. Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine is the recommended prevention strategy for the next pregnancy — AL is not used for IPTp. |
| 3rd trimester | First-line. WHO-recommended treatment for uncomplicated P. falciparum malaria. Heightened vigilance for fetal complications: continuous fetal monitoring during acute illness, ultrasound assessment for fetal growth restriction, and uterine activity monitoring for preterm labour. Hypoglycaemia monitoring is especially important as both falciparum malaria and the physiological insulin response of late pregnancy predispose to severe hypoglycaemia. If delivery occurs within 28 days of AL treatment, inform neonatologist. IV artesunate is mandatory for any features of severe malaria. At term, neonatal monitoring for jaundice is advisable given malaria-associated haemolysis in the mother and potential (low) neonatal drug exposure via placenta. |
dizziness
Loading safety data…
Clinical note
Artemether-lumefantrine (AL) is a fixed-dose artemisinin-based combination therapy (ACT) and the WHO-recommended first-line treatment for uncomplicated Plasmodium falciparum malaria in the second and third trimesters of pregnancy. In the first trimester, data are more limited but increasingly reassuring: large observational studies including the WHO-coordinated WWARN database and the PREGACT trial have not demonstrated increased rates of miscarriage, stillbirth, or major congenital malformations compared to quinine. WHO updated guidance (2015, reaffirmed 2023) endorses ACT use — including AL — in the first trimester when it is the only available effective treatment, acknowledging that untreated or undertreated falciparum malaria in pregnancy carries high risks of maternal death, severe anaemia, hypoglycaemia, pulmonary oedema, cerebral malaria, miscarriage, preterm birth, fetal growth restriction, and perinatal death. Quinine plus clindamycin remains the preferred regimen in settings where first-trimester ACT alternatives exist and clinical capacity allows. The drug is not indicated for severe or complicated malaria (IV artesunate is the standard of care) or for non-falciparum species without falciparum co-infection.
| Placental transfer | Artemether and its active metabolite dihydroartemisinin (DHA): Both cross the placenta. DHA has been detected in cord blood following artemether treatment. Given the very short half-life (~1–2 hours), fetal exposure is transient. Animal data demonstrating embryotoxicity suggest sufficient placental transfer exists at high doses; at human therapeutic exposures, fetal concentrations are expected to be low and transient. Lumefantrine: Placental transfer is expected to be limited due to its extremely high lipophilicity (logP ~7), very high protein binding (>99%), and large molecular weight (528 g/mol). Quantitative cord blood data are sparse in humans, but pharmacokinetic modelling suggests low fetal lumefantrine exposure. Paradoxically, this low placental transfer of lumefantrine (the partner drug providing post-treatment prophylaxis) may contribute to the observed reduction in lumefantrine AUC in pregnancy and reduced post-treatment prophylactic effect in endemic settings — leaving pregnant women more vulnerable to rapid re-infection after treatment. |
| Breastfeeding | Both artemether and lumefantrine are excreted into breast milk in small quantities. Artemether and its active metabolite dihydroartemisinin (DHA) have very short half-lives and are expected to be present in milk at low concentrations. Lumefantrine has high lipophilicity and high protein binding; milk transfer is likely limited but quantitative data are sparse. The relative infant dose (RID) for lumefantrine has not been precisely established in human lactation studies, but based on pharmacokinetic modelling, infant exposure via breast milk is estimated to be low. Given that malaria itself poses grave risk to the breastfeeding mother and the infant if the mother is untreated, breastfeeding should continue during and after AL treatment. WHO explicitly endorses continued breastfeeding during ACT therapy. Monitor nursing infant for jaundice (theoretical haemolysis risk in G6PD-deficient neonates, though systemic neonatal lumefantrine exposure from breast milk is expected to be very low). |
